Lv1
90 积分 2020-12-01 加入
Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome
1天前
已完结
中国肝癌分期Ⅲa期巨大肝癌术后辅助免疫治疗的疗效分析
28天前
已关闭
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC
1个月前
已完结
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients
6个月前
已完结
单中心真实世界数据分析：表皮生长因子受体常见和少见突变型非小细胞肺癌靶向治疗疗效比较
7个月前
已完结
新生儿高胆红素血症诊断和治疗专家共识
1年前
已完结
The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer
1年前
已完结
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
1年前
已完结
Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non–Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non–Small-Cell Lung Cancer
1年前
已完结
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
1年前
已完结
皖公网安备34019202002308
